Evidence map›Paper›PMID 40694102›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Dosimetry and kinetic modelling of [

Michel Koole, Mark E Schmidt, Anja Hijzen, Marie Cohilis, Corinne Vandermeulen, Kim Serdons, Sofie Celen, Guy Bormans, Michael Maher, Anna Katrin Szardenings and 4 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03270579 (An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03270579 phase1completednot on this map

An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

TypeinterventionalSponsorJanssen Research & Development, LLCRan2017 to 2018Enrolled8ConditionsHealthyArms[18F]JNJ-64511070
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Preclinical Evaluation of [Molecular imaging and biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michel Koole *Nuclear Medicine and Molecular Imaging, Dept. Imaging and Pathology, KU Leuven, Leuven, Belgium.ORCID 0000-0001-5862-640X
Mark E Schmidt *Janssen Research and Development, Beerse, Belgium.ORCID 0000-0003-3417-8977
Anja HijzenJanssen Research and Development, Beerse, Belgium.
Marie CohilisNuclear Medicine and Molecular Imaging, Dept. Imaging and Pathology, KU Leuven, Leuven, Belgium.ORCID 0000-0001-8102-7747
Corinne VandermeulenCenter for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-1954-7554
Kim SerdonsNuclear Medicine, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium.ORCID 0000-0001-8690-6679
Sofie CelenNuclear Medicine and Molecular Imaging, Dept. Imaging and Pathology, KU Leuven, Leuven, Belgium.ORCID 0000-0002-6742-7469
Guy BormansLaboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-0335-7190
Michael MaherJanssen Research and Development, Titusville, NJ, USA.
Anna Katrin SzardeningsJanssen Research and Development, La Jolla, CA, USA.ORCID 0000-0002-9887-7868
Wei ZhangJanssen Research and Development, Beerse, Belgium.
Hartmuth KolbJanssen Research and Development, La Jolla, CA, USA.ORCID 0000-0003-2414-5792
Jan de HoonCenter for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-5215-9836
Koen Van LaereNuclear Medicine and Molecular Imaging, Dept. Imaging and Pathology, KU Leuven, Leuven, Belgium. koen.vanlaere@kuleuven.be.ORCID 0000-0001-5200-7245

Funding

Janssen Research and Development Janssen Research and Development
6 · The paper itself

Abstract

purposeThe α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA-R) are the primary determinants of synaptic strength in most glutamatergic neurons. Inhibition or negative modulation of AMPA-Rs is an attractive strategy for therapeutic intervention in central nervous system (CNS) disorders characterized by excessive neuronal activity. We report the clinical qualification of a AMPA-R associated TARP-γ8 specific PET ligand [

methodsWhole body dosimetry was performed in 3 healthy male subjects (22-41y). Upon estimation of the normalized cumulated activity (NCA), the effective dose (ED) was calculated using OLINDA v1.1. In a second part, 120-minute dynamic brain scanning with arterial blood sampling was done in five healthy males (25-53y) to determine the appropriate kinetic model and evaluate time stability of total distribution volume (V

resultsThe average ED (± SD) was 15.6 ± 1.0 µSv/MBq. Brain uptake of [

conclusion[

trial registrationClinicalTrials.gov database with clinical trial number NCT03270579, Registered 31 August 2017.

Indexed as

BrainModels, BiologicalPositron-Emission TomographyRadiopharmaceuticalsReceptors, AMPAAdultFluorine RadioisotopesHumansKineticsLigandsMaleMiddle AgedRadiometryTissue DistributionYoung AdultFluorine RadioisotopesLigandsRadiopharmaceuticalsReceptors, AMPA[18F]JNJ-64511070AMPA-R TARP-γ8Brain kinetic modelingDosimetryHealthy subjectsPETTime stability

Identifiers

PMID40694102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.